Beam Therapeutics Inc. Overview
Pro stress-test →Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on proprietary base editing technology. Base editing is designed to enable precise, predictable and efficient single base changes at targeted genomic sequences without making double-stranded breaks in the DNA. The company is advancing a portfolio of programs targeting serious genetic diseases including sickle cell disease, alpha-1 antitrypsin deficiency, and phenylketonuria.
Strategic Profile
Pro stress-test →Beam is establishing the leading, fully integrated platform for precision genetic medicines with integrated gene editing, delivery and internal manufacturing capabilities. Backed by a strong balance sheet and expected cash runway into 2029, the company believes it is uniquely positioned to translate scientific innovation into meaningful, lasting benefit for patients with serious diseases. The company has achieved key regulatory alignment milestones with the FDA and secured non-dilutive capital to advance late-stage clinical programs.
Competitive Landscape
Pro stress-test →Verve Therapeutics, Prime Medicine, CRISPR Therapeutics, Editas Medicine, and Sharp Therapeutics are among competitors of Beam Therapeutics. Top competitors include Verve, eGenesis and Tessera Therapeutics. Beam differentiates through its proprietary base editing platform, integrated manufacturing capabilities, and focus on precision genetic medicines with predictable outcomes across multiple disease indications.
Industry Context
Beam Therapeutics Inc. operates in Biotechnology / Precision Genetic Medicine.
Key facts
Founded: 2017 · Headquarters: Cambridge, MA · Employees: 572 · Revenue: $55.7M · Market cap: $3.59B